UTRECHT, Nov. 09, 2018 (PENNYSTOCKS.NEWS) – It’s been a hard, tough road for the global biopharmaceutical company Alexion Pharmaceuticals Inc. after hitting an all-time high in July, 2015 at $204. In the aftermath of this succes ALXN struggled hard and held on desperately, trying not to crash face first. Eventually, resulting in an all-time low of $97 in May, 2017. Almost as if ALXN went to the bottom to see the light, stock prices grew to $146 only four months later. Ever since, the stock prices have been fluctuating between between $102 and $140. Currently valuated at $127.
High Risk High Reward?
Over the past year ALXN has been shifting to top and bottom at lightning speed. Beginning at a price of $116 on 9 nov. 2017 the stock begins to drop to $108 one month later on december. Only to rise to $128, again, one month later. This pattern repeated itself month after month until in sept. 2018 the stock reached a high of $139. It immediatly fell down reaching $112 on oct. 31, 2018. Two days after the collapse the enterprise revealed in a press release that the acquisition of Syntimmune has been succesfully completed. Ludwig Hantson, Ph.D., Chief Executive Officer of Alexion, said: ‘’We’ve made significant progress rebuilding our pipeline this year, and the acquisition of Syntimmune is another critical step in continuing to expand and diversify our portfolio.’’. He also later stated: ‘’We are rapidly advancing the current development programs and look forward to beginning two pivotal programs next year, including one in warm autoimmune hemolytic anemia.’’. Positive words from the CEO, what else is to be expected. Either way, it does sound promising and Alexion is serving patients and families affected by rare diseases through discovery, development and commercialization of life-changing therapies.
The acquisition gives value to the company’s growing pipeline with the addition of clinical-stage SYNT001, a humanized antibody with the potential to treat a number of rare diseases.
Following the press release stocks went go up. Every time ALXN comes near the $140 mark, resistance appears. In the last eight days Alexion Pharmaceuticals Inc. kept growing to $127 today. This month has only just begun, meaning there’s a chance ALXN stock might rise for a while. It has the potential to skyrocket as it has shown in the past, but will it? Maybe the stock has had it’s best days and found a comfortable place in the market. With fluctuations like these, buying and selling at the right time seems crucial. Top analyst Hartaj Singh selected ALXN as his top stock to buy for february-march, 2017. Singh was confident Alexion could explode from just $115 to $175. So far it hasn’t happened yet, but witnessing the steep uprise of ALXN over the last eight days might be a sign Singh is going to be right after all.
Alexion Pharmaceuticals Inc. (ALXN) is a global biopharmaceutical corporation based in the U.S.A. They best known for their creation Soliris, a drug used to treat rare blood disorders. Founded in 1992, Alexion shines light on those who feel isolated and alone. Following this noble path, Alexion gave hope to thousands of people. Their goal is to deliver medical breakthroughs where none currently exist. Driven by the fact lives are at stake, Alexion has pioneered the complex field of complement biology and delivers solutions to challenges for patients with devastating complement-mediated and metabolic disorders. Soliris being the world’s first approved terminal complement inhibitor. In their officially released third quarter report on oct. 24, 2018 Chief Financial Officer, Paul Clancy revealed a 18% sales growth of Soliris and a 34% grew in sales for Metabolic. Total revenues going up by 20%. They also have two highly innovative enzyme replacement therapies for patients with life-threatening and extremely-rare metabolic disorders. Alexion’s ambition is to be the global leader in rare diseases.
Feel free to contact the writer and let him know what you think of the article: [email protected]
All information PennyStocks.News has gathered to write this information are from a reliable source, but we cannot guarantee that what is written are facts. The articles that are published and written on PennyStocks.News is our opinion regarding to it and should not be seen as an advice to buy or sell any particular stock or securities.
Pennystocks.News LLC was established to research a wide range of companies listed on the NYSE, NASDAQ, AMEX, OTCBB and Pink Sheets. We bring to you only the best penny stock news and trending stocks through our blogs, Social Media and E-mail newsletter.